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Table 1
HLA-DR Genotypes in 937 Swedish MS Patients and 739
Swedish Controls
SPECIFICITIES
Genotype Referencea ODDS RATIO 95% CI Pb
DR15/DR15 DRX/DRX 8.3 4.8–14.5 !.0001
DR15/DRX DRX/DRX 3.0 2.4–3.9 !.0001
DR15/DR15 DR15/DRX 2.7 1.6–4.8 .0002
DR17/DR17 DRX/DRX 6.1 2.5–15.2 !.0001
DR17/DRX DRX/DRX .93 .68–1.3 .64
DR17/DR17 DR17/DRX 6.6 2.6–16.8 !.0001
DR15/DR17 DRX/DRX 3.9 2.5–6.1 !.0001
DR15/DR17 DR15/DRX 1.3 .81–2.0 .32
DR15/DR17 DR17/DRX 4.2 2.6–6.9 !.0001
a DRX indicates not DR15 or DR17.
b Uncorrected two-sided probability values.
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Modes of Action of HLA-DR Susceptibility
Speciﬁcities in Multiple Sclerosis
To the Editor:
In a recent analysis of genotypes associatedwithmultiple
sclerosis (MS [MIM 126200]) in a large data set of
American families, Barcellos et al. (2003) demonstrated
a dose effect of the HLA class II haplotype DR2
(DRB1*1501 [MIM 142857], DQB1*0602) on the risk
of MS. In a total data set of 808 affected and 1,574
unaffected individuals, from 549multicase or single-case
kinships, carriage of one or two copies of DR2 con-
ferred, respectively, 2.7-fold and 6.7-fold risks, as com-
pared to genotypes lacking the haplotype.
We have performed a similar analysis in a data set of
937 Swedish sporadic MS cases and 739 Swedish con-
trols. All patients were diagnosed withMS in accordance
with the recommendations of McDonald et al. (2001);
the mean age at onset was 31.4 years, 52 patients (5.5%)
suffered from primary-progressive MS, and the female-
to-male ratio was 2.6:1. HLA-DRB1 genotyping was
performed by PCR ampliﬁcation with sequence-speciﬁc
primers and with a resolution corresponding to standard
serological typing (Olerup and Zetterquist 1992). Ge-
notypes for 786 patients had been used in a previous
study (Masterman et al. 2000). Permission to perform
the study was granted by the ethics committee of Ka-
rolinska Institutet, and all patients and controls gave
their informed consent. Probability values for Hardy-
Weinberg-equilibrium (HWE) testing were calculated by
the x2 test; probability values for comparisons of ge-
notype counts in patients and controls were calculated
by the Fisher exact test, and 95% CIs of odds ratios
were determined byWoolf’s method and the use of Instat
(GraphPad Software 1993).
As we have reported elsewhere (Masterman et al.
2000), both the DR2 split DR15 and the DR3 split
DR17 are associated withMS in the Swedish population.
Thus, we tested the modes of action of both these spec-
iﬁcities, designating as reference “DRX” any speciﬁcity
other than DR15 or DR17. Control genotypes were in
HWE ( , 5 df, ), but patient genotypes2x p 9.6 Pp .09
were not ( , 5 df, ), the largest de-2x p 52.3 P ! .0001
viations being an excess of DR17 homozygotes (26 ob-
served vs. 13.6 expected, ) and a paucity of2x p 11.3
DR17 heterozygotes (92 observed vs. 119.8 expected,
).2x p 6.5
The risks conferred by DR15/DR15 and DR15/DRX
in the present study (table 1, rows 1–3) are virtually
identical to those reported by Barcellos et al. (2003) for
DR2-bearing genotypes in a subset of 362 singleton fam-
ilies, conﬁrming the dominant, dose-dependent effect of
the DR2 haplotype (and DR15 speciﬁcity) on MS sus-
ceptibility. By contrast, the mode of action of DR17,
though also dose-dependent, is clearly recessive (table 1,
rows 4–6), with two copies of DR17 conferring a 6.1-
fold risk of MS and one copy conferring no risk at all.
Indeed, a comparison of the risks conferred by DR15/
DRX and DR15/DR17 further illustrates that a single
copy of DR17 has no effect on the risk of MS (table 1,
rows 7–9).
Although the mechanism by which alleles of classical
or nonclassical HLA genes may predispose carriers to
MS is still unknown, Oksenberg et al. (1996) have pro-
posed six models. The ﬁrst three involve presentation of
encephalitogenic peptides by HLA molecules (the deter-
minant model, the thymic-selection model, and the mo-
lecular-mimicry model), and the second three involve
either regulation of the expression levels of immunemol-
ecules (the cytokine-regulation model and the aberrant-
expression model) or proximity of associatedHLA genes
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to disease-predisposing non-HLA genes (the linkage dis-
equilibrium [LD] model).
Although the association of two HLA-DR speciﬁcities
to MS is not inconsistent with any of the single-mech-
anism models mentioned above—it could be explained,
for example, by allelic heterogeneity (or even locus het-
erogeneity, given the extensive LD of the HLA region)—
at the same time, the contrasting modes of action of
DR15 and DR17 support an alternative, two-mechanism
model. Indeed, to explain the multiple HLA class II as-
sociations in rheumatoid arthritis, Zanelli et al. (2000)
have proposed such a model, involving both recessive
loss of immune protection and dominant exacerbation
of ongoing inﬂammation.
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Nuclear Factor TDP-43 Binds to the Polymorphic TG
Repeats in CFTR Intron 8 and Causes Skipping of
Exon 9: A Functional Link with Disease Penetrance
To the Editor:
In the January 2004 issue of AJHG, Groman et al. pub-
lished a collaborative study on the disease penetrance of
a common abbreviated tract of ﬁve thymidines (T5) in
intron 8 of the CFTR gene (MIM 602421). By analyzing
a large number of affected individuals presenting with
male infertility or nonclassical cystic ﬁbrosis (CF [MIM
219700]), they found that the pathogenic or benign ef-
fect of T5 correlated with variations in a TG repeat
sequence just upstream of the polypyrymidines. In par-
ticular, longer TG repeats (12 or 13) are associated with
disease phenotypes, and 91% of affected individuals, as
opposed to 22% of unaffected ones, have repetitions of
12 or 13 TGs. Although the modiﬁer effect of the TG
repeats on the T5 variant has been proposed elsewhere
(Cuppens et al. 1998), the principal novelty of the Gro-
man et al. study lies in the high number of patients
analyzed from different regions. As the T5 allele is found
in ∼10% of the general population, the results of this
study strongly indicate that determination of the TG
repeats may have a signiﬁcant diagnostic value.
The pathologies studied by Groman et al. are in line
with the growing number of human diseases resulting
from pre-mRNA splicing alterations and, speciﬁcally,
those diseases caused by mutations in cis-acting elements
(the TG and T repeats) that disrupt the use of alternative
splice sites, as recently reviewed by Faustino and Cooper
(2003). In this speciﬁc case, the pathogenetic role of
these repeats is owing to their effects on CFTR exon 9
at the level of pre-mRNA splicing, with longer UG re-
peats (and short U tracts) increasing exon 9 skipping
and leading to the production of a nonfunctional protein
(Delaney et al. 1993; Strong et al. 1993).
An obvious question, not taken into consideration in
the study by Groman et al., is what factor(s) or mech-
